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Introduction
Sepsis is one of  the most common causes of  death on intensive care units (ICUs) and is defined as a 
life-threatening organ dysfunction secondary to an infection (1, 2). In addition to respiratory failure, septic 
cardiomyopathy is a common organ dysfunction in septic shock and is clearly associated with prolonged 
hospital stays and increased mortality (3, 4). Septic cardiomyopathy is a functional restriction of  the heart 
that results in a ventricular dilation and reduced contractility (5, 6). To date, however, no specific therapeu-
tic strategies are available.
The tissue injury associated with sepsis results in the release of  a variety of  damage-associated molec-
ular patterns (DAMPs) (7, 8). Extracellular RNA (eRNA) belongs to this heterogeneous group of  DAMPs 
and includes several types of  RNA present in the extracellular environment, including microRNA (miR-
NA), transfer RNA (tRNA), small interfering RNA (siRNA), and long noncoding RNA (lncRNA). eRNA 
is released as a result of  tissue injury and necrotic cell death from a variety of  cells, including cardiomyo-
cytes (9), and may play a role in differentiation, chromatin modification, and inflammation as well as tissue 
injury and repair (10–14). However, it is unknown whether eRNA plays a role in septic cardiomyopathy 
and cardiac apoptosis. Playing a decisive role in septic cardiomyopathy (15), apoptosis represents a pro-
grammed, caspase-mediated cell death that is triggered by intrinsic or extrinsic signaling pathways.
In 1988, Steven Benner described eRNA as an intercellular “communicator” and hypothesized that the 
activity of  eRNA is modulated by endogenous ribonucleases (RNases) (16). RNases belong to a group of  
host-defense peptides, which are ubiquitously expressed in several tissues and body fluids. As a part of  the 
innate immune system, RNases modulate local and systemic inflammatory responses induced by exoge-
Septic cardiomyopathy is a life-threatening organ dysfunction caused by sepsis. Ribonuclease 1 
(RNase 1) belongs to a group of host-defense peptides that specifically cleave extracellular RNA 
(eRNA). The activity of RNase 1 is inhibited by ribonuclease-inhibitor 1 (RNH1). However, the role of 
RNase 1 in septic cardiomyopathy and associated cardiac apoptosis is completely unknown. Here, 
we show that sepsis resulted in a significant increase in RNH1 and eRNA serum levels compared 
with those of healthy subjects. Treatment with RNase 1 resulted in a significant decrease of 
apoptosis, induced by the intrinsic pathway, and TNF expression in murine cardiomyocytes exposed 
to either necrotic cardiomyocytes or serum of septic patients for 16 hours. Additionally, treatment 
of septic mice with RNase 1 resulted in a reduction in cardiac apoptosis, TNF expression, and septic 
cardiomyopathy. These data demonstrate that eRNA plays a crucial role in the pathophysiology of 
the organ (cardiac) dysfunction in sepsis and that RNase and RNH1 may be new therapeutic targets 
and/or strategies to reduce the cardiac injury and dysfunction caused by sepsis.
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nous pathogens and endogenous danger molecules (17). Specifically, RNase 1 cleaves eRNA and, therefore, 
modulates and/or limits the levels of  circulating eRNA (17). As an endogenous modulator of  RNase 1, the 
human ribonuclease-inhibitor 1 (RNH1) is ubiquitously expressed in a variety of  tissues and binds to and 
inactivates RNase 1 with a high affinity (18, 19). RNH1 and RNase 1 have complementary structures (20). 
Primarily induced by oxidative stress (20), RNH1 regulates the activity of  RNases and, thus, plays a crucial 
role in the immunomodulatory and host-defense functions of  RNases (21). However, the respective roles of  
RNase 1 and RNH1 in septic cardiomyopathy and cardiac apoptosis are unknown.
The aim of  this reverse-translational study was to investigate (a) the levels and kinetics of  RNH1 and 
the eRNA profile in the serum of  patients with sepsis and healthy subjects (control), (b) the potential of  
RNase 1 to reduce apoptosis in cardiomyocytes, and (c) whether the application of  RNase 1 attenuates 
septic cardiomyopathy and cardiac apoptosis in a murine model of  polymicrobial sepsis.
Results
RNH1 is elevated in serum of  septic patients. We recently reported that serum levels of  RNase 1 are substan-
tially elevated in the early phase of  sepsis (22). Because RNH1 inhibits the enzymatic activity of  RNase 1, 
serum levels of  RNH1 in septic patients (n = 21) were investigated on the day of  and 3 days after diagnosis. 
Moreover, serum levels of  RNH1 were analyzed in age- and sex-matched healthy subjects (n = 10). The 
characteristics of  the study population according to the groups are shown in Supplemental Table 1 (sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.131571DS1). In 
healthy subjects, the RNH1 concentrations were below the detection limit of  the ELISA used (1.563 ng/
mL; n = 10; Figure 1A). In contrast, a mean concentration of  4.22 ± 1.00 ng/mL RNH1 was detected in 
serum of  septic patients at time of  diagnosis (Figure 1A), which rose further to 5.29 ± 1.36 ng/mL 3 days 
after diagnosis of  sepsis (P < 0.05 when compared with healthy subjects; Figure 1A).
Levels of  eRNA are elevated in serum of  septic patients. After demonstrating elevated serum levels of  RNase 
1 and of  its inhibitor RNH1 in patients with sepsis, the levels of  eRNA in serum of  septic patients (n = 21) 
and healthy volunteers (n = 10) were measured 3 days after diagnosis. The different sizes of  eRNA pre-
sented in serum of  septic patients and healthy volunteers were also investigated. A mean concentration of  
59.64 ± 4.92 ng/μL eRNA was measured in healthy subjects. In contrast, in serum of  septic patients 3 days 
after diagnosis a significantly increased mean concentration of  105.6 ± 4.85 ng/μL eRNA was detected 
(P < 0.05 when compared with healthy subjects; Figure 1B). The electropherograms from serum of  septic 
patients 3 days after diagnosis (n = 21) showed a higher variety of  eRNA compared with heathy subjects 
(n = 10; Figure 1C). In healthy volunteers, a more uniform eRNA size distribution was observed, with the 
highest sample intensity in serum of  healthy volunteers between 100 and 500 nt. In contrast, serum of  sep-
tic patients showed a much higher variance in eRNA size distribution and a much higher sample intensity, 
which is caused by the higher concentration of  eRNA in serum of  septic patients (Figure 1C).
RNase 1 reduces the caspase-3 activation and apoptosis induced by necrotic cardiomyocytes. As demonstrated in ear-
lier studies, septic cardiomyopathy is associated with cardiac apoptosis and necrotic cell death (23, 24). We 
investigated the potential induction of apoptosis by eRNA released from necrotic cardiomyocytes (NC) by 
exposing murine cardiomyocytes to NC. We also investigated whether RNase 1 reduces the degree of apoptosis 
caused by the eRNA released from NC. Cardiomyocytes exposed to NC, in the absence of RNase 1 treatment, 
showed a significant increase of cleaved/activated caspase-3 when compared with unstimulated cells measured 
by immunofluorescence (P < 0.01; Figure 2, A and B). Treatment with RNase 1, however, resulted in a decrease 
in caspase-3 activation (P < 0.05; Figure 2, A and B). Because eRNA leads to an increased expression of TNF 
via binding to TLR-3 and -7 (23–25), TNF mRNA expression was investigated in this setting. We found that 
cardiomyocytes stimulated with NC in the presence of RNase 1 showed a significant reduction in the expression 
of TNF mRNA when compared with cardiomyocytes challenged with NC in the absence of RNase 1 (P < 0.05; 
Figure 2C). Additionally, we investigated the amount of total eRNA released from 105 NC/mL and from the 
cell supernatants of unstimulated and/or stimulated cardiomyocytes. In cell supernatant of untreated cardiomy-
ocytes, the mean concentration of eRNA was 0.85 ± 0.07 ng/mL. In contrast, we found significantly increased 
eRNA concentrations in the supernatant of cardiomyocytes exposed to NC for 16 hours (1.17 ± 0.03 ng/mL) as 
well as in 105 necrotic cells/mL (1.15 ± 0.07 ng/mL; P < 0.05; Figure 2D).
Next, we aimed to confirm that apoptosis was the predominant type of  cell death in cardiomyocytes 
exposed to NC by TUNEL labeling. Unstimulated cardiomyocytes (control) did not show any TUNEL 
fluorescence (Figure 3A). However, in cardiomyocytes exposed to NC for 16 hours, there was an increased 
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number of  TUNEL+ cells (significant increase of  a mean 3.58 ± 0.47 relative TUNEL fluorescence com-
pared with unstimulated cells; P < 0.001; Figure 3, A and B). In contrast, the exposure of  cardiomyocytes 
to necrotic cells in the presence of  RNase 1 resulted in a smaller number of  TUNEL+ cells (mean 1.91 ± 
0.42 relative TUNEL fluorescence compared with cardiomyocytes exposed to necrotic cells in absence of  
RNase; Figure 3, A and B). The amount of  apoptosis was further quantified and/or confirmed using flow 
cytometry. Relatively few unstimulated cells were positive for annexin V (7.57% ± 0.36%), 7-aminoactino-
mycin D (7-AAD) (0.97% ± 0.30%), and annexin V plus 7-AAD (0.54% ± 0.12%). The main part of  the 
population was represented by living cells (Figure 3C). Cardiomyocytes exposed to 1 × 105 NC contained 
13.36% ± 2.17% annexin V, 1.26% ± 0.12% 7-AAD and 0.51% ± 0.01% annexin V+ and 7-AAD+ cells (Fig-
ure 3C). However, exposure of  NC in the presence of  RNase 1 resulted in 7.55% ± 1.09% annexin V, 0.82% 
± 0.21% 7-AAD, and 0.96% ± 0.77% annexin V+ and 7-AAD+ cells (Figure 3C). The amount of  annexin 
V+ cells significantly increased in cardiomyocytes exposed to NC compared with unstimulated cells (P < 
0.001; Figure 3D), which was significantly diminished by the addition of  RNase 1 (P < 0.001; Figure 3D).
RNase 1 reduces the caspase-3 activation induced by serum of  septic patients. After demonstrating serum levels 
of  RNH1 as well as total eRNA are significantly elevated in serum of  septic patients (both P < 0.05), we 
investigated caspase-3 activation and TNF mRNA expression in murine cardiomyocytes challenged with 
serum of  septic patients, as a reverse translational approach. Specifically, we aimed to confirm the potential 
protective/antiapoptotic effect of  RNase 1 in this setting. When compared with unstimulated cells, cardio-
myocytes exposed to serum of  septic patients (in the absence of  RNase 1) showed a significant increase in 
the cleavage of  caspase-3 as well as an increase in the expression of  TNF mRNA (P < 0.05; Figure 4, A–C). 
Figure 1. RNH1 and total extracellular RNA serum levels. (A) RNH1 levels of healthy subjects (n = 10) and ICU patients 
with sepsis on the day of diagnosis (Sepsis DD) and 3 days after diagnosis (Sepsis D3; both n = 21) are displayed. A 
1-way ANOVA followed by Bonferroni test was used for multiple comparisons. Data are presented as dot plot with the 
mean ± SEM. (B) Total eRNA levels from serum of healthy subjects (n = 10) and septic patients (n = 21) 3 days after 
diagnosis are demonstrated. An unpaired t test (2-tailed) was used for statistical analysis. Data are presented as dot 
plot with the mean ± SEM. (C) The eRNA size distribution from serum of healthy subjects (n = 10) and septic patients 3 
days after diagnosis (n = 21) are presented in an electropherogram and a gel image. The first peak (between 10 and 100 
nt) of the electropherograms represented the ladder. §P < 0.05 versus control/healthy. RNH1, ribonuclease-inhibitor 1; 
eRNA, extracellular RNA.
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In contrast, RNase 1 attenuated the increases in both caspase-3 activation and TNF mRNA expression in 
cardiomyocytes challenged with serum of  septic patients (P < 0.05; Figure 4, A–C).
TLR3 inhibition reduces the caspase-3 activation induced by eRNA. After demonstrating that apoptosis and 
TNF expression were induced by NC and serum of  septic patients, which both contain eRNA, caspase-3 
activation in cardiomyocytes challenged with eRNA isolated from cardiomyocytes was investigated. A sig-
nificantly increased relative caspase-3 activation was detected in cardiomyocytes exposed to eRNA, when 
compared with unstimulated cardiomyocytes (1.26 ± 0.08; P < 0.05; Figure 4D). Furthermore, we wanted 
to investigate whether caspase-3 activation in cardiomyocytes exposed to eRNA is caused by binding to 
TLR3. We found a decreased relative caspase-3 activation in cardiomyocytes stimulated with eRNA in 
the presence of  a TLR3 inhibitor (CU CPT 4a) compared with cardiomyocytes exposed to eRNA in the 
absence of  the TLR3 inhibitor (1.10 ± 0.11; Figure 4D).
RNase 1 improves the cardiovascular function and reduces cardiac apoptosis in murine polymicrobial sepsis. After 
demonstrating that the exposure of  murine cardiomyocytes in the presence of  RNase 1 resulted in reduced 
apoptosis (when challenged with NC or serum of septic patients), we next investigated the effect of  RNase 1 
on cardiac function and cardiac apoptosis in a murine model of  polymicrobial sepsis. When compared with 
sham-operated mice, cecal ligation and puncture–induced (CLP-induced) sepsis resulted in a substantial car-
diac dysfunction (measured as a reduction of  ejection fraction [EF], fractional shortening [FS], and fractional 
area change [FAC] by echocardiography) (all P < 0.001; Figure 5). Treatment with RNase 1, however, signifi-
cantly attenuated the cardiac dysfunction associated with CLP-sepsis, as indicated by higher values of  EF, FS 
(both P < 0.001; Figure 5), and FAC (P < 0.01; Figure 5) compared with vehicle-treated CLP mice (control). 
To analyze the cardiac dysfunction in sepsis and the potential beneficial effects of  RNase 1, we further inves-
tigated the left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and 
stroke volume (SV) as well as the cardiac output and the heart rate before echocardiography. Of significance, 
no change in LVEDV was detected between the groups (Figure 5E). In CLP-sepsis, a significant increased 
LVESV was measured, when compared with sham-operated mice (P < 0.01; Figure 5). RNase 1 treatment of  
CLP animals, however, resulted in a decrease of  LVESV (when compared with vehicle-treated CLP-sepsis). 
Accordingly, when compared with sham-operated mice, CLP-sepsis resulted in a significant decreased SV, 
heart rate, and cardiac output, which was significantly diminished by RNase 1 treatment (all P < 0.01; Figure 
5). Sham-operated animals treated with RNase 1 showed no changes in any of  the preceding parameters, 
when compared with sham-operated animals treated with vehicle (Figure 5).
Figure 2. RNase 1 treatment results in decrease of cleaved caspase-3 
immunofluorescence and TNF mRNA expression in murine cardiomyo-
cytes exposed to necrotic cardiomyocytes. (A) Cardiomyocytes exposed 
to 105 necrotic cardiomyocytes (NC) for 16 hours in presence (RNase + 
NC) or absence of 2.8 U/mL RNase 1 were stained with Phalloidin, DAPI, 
and anti-cleaved caspase-3 and compared with unstimulated cells 
(control). Phalloidin represents the cytosol (red), DAPI stained represents 
the nuclei (blue), and green immunofluorescence represents the cleaved 
caspase-3 (cl. caspase 3) expression. Scale bars: 100 μm. (B) Quantifica-
tion of cleaved caspase 3 immunofluorescence (all n = 3). A 1-way ANO-
VA followed by Bonferroni test was used for multiple comparisons. Data 
are presented as dot plot with the mean ± SEM. (C) Relative TNF mRNA 
expression of cardiomyocytes exposed to NC in presence of RNase 1 
compared with cardiomyocytes stimulated in absence of RNase 1 (both n 
= 3). An unpaired t test (2-tailed) was used for statistical analysis. Data 
are presented as dot plot with the mean ± SEM. (D) Total extracellular 
RNA in cell supernatant of cardiomyocytes exposed to NC for 16 hours 
and untreated cells (both n = 3) as well as eRNA level in 105 NC/mL (n 
= 2). A 1-way ANOVA followed by Bonferroni test was used for multiple 
comparisons. Data are presented as dot plot with the mean ± SEM. §P < 
0.05 versus control; #P < 0.05 versus NC. NC, necrotic cardiomyocytes; 
RNase, ribonuclease 1.
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To gain a better understanding of  the underlying signaling events involved in the observed beneficial 
effects of  RNase 1 on sepsis-associated cardiomyopathy, we investigated the relevant apoptosis pathways in 
cardiac tissue at 24 hours after onset of  sepsis (e.g., the time point at which cardiac function was evaluated). 
When compared with sham-operated animals, CLP-sepsis resulted in a significant increase in Bax levels 
as well as caspase-9 and caspase-3 activation (P < 0.001; P < 0.01; P < 0.01; Figure 6). In contrast to vehi-
cle-treated animals, the treatment of  CLP mice with RNase 1, however, significantly attenuated the increas-
es in Bax levels and the associated activation of  caspase-9 and caspase-3 associated with sepsis (P < 0.01; 
P < 0.01; P < 0.05; Figure 6). Furthermore, CLP-sepsis resulted in a decrease in Bcl-2 levels in the heart (P 
< 0.05; Figure 6), an effect that was also significantly attenuated by RNase 1 treatment (P < 0.01; Figure 
6). To confirm that apoptosis is induced by CLP in the heart, we analyzed the number of  apoptotic cells 
in heart tissue by TUNEL labeling. When compared with sham-operated animals, CLP-sepsis resulted in 
an increase in relative TUNEL fluorescence (mean 2.73 ± 0.71 relative TUNEL fluorescence; Figure 6, E 
and F). The treatment of  CLP-sepsis with RNase 1 resulted in a decrease of  relative TUNEL fluorescence 
compared with vehicle-treated CLP animals (mean 1.45 ± 0.60 relative TUNEL fluorescence; Figure 6, E 
and F). However, treatment of  sham-operated mice with RNase 1 did not result in an increase in TUNEL 
fluorescence (mean 0.64 ± 0.26 relative TUNEL fluorescence; Figure 6, E and F).
After detecting elevated serum levels of  RNH1 and total eRNA in patients with sepsis, we investigated 
serum levels of  RNase 1, RNH1, and total eRNA in murine polymicrobial sepsis. We also analyzed the TNF 
serum levels in CLP-sepsis to gain a better understanding of  the underlying mechanisms and associations 
between the eRNA concentration and the proinflammatory/proapoptotic cardiac response. In sham-oper-
ated mice treated with vehicle or RNase 1, RNase 1 serum levels were 236.86 ± 8.11 ng/mL and 287.32 ± 
19.37 ng/mL (Figure 7B). In contrast, untreated sepsis (24 hours after CLP challenge) resulted in significantly 
decreased RNase 1 serum levels (69.68 ± 27.16 ng/mL RNase 1; P < 0.05 when compared with sham-op-
erated mice; Figure 7B), whereas septic mice treated with RNase 1 showed a mean RNase 1 concentration 
of  108.5 ± 22.70 ng/mL (Figure 7B). Furthermore, the treatment of  CLP mice with RNase 1 resulted in an 
improved renal dysfunction and hepatocellular injury (Supplemental Figure 1). In sham-operated mice treat-
ed with vehicle, the TNF and RNH1 concentrations were below the detection limit of  the ELISA used (31.3 
pg/mL and 0.78 ng/mL; Figure 7, A and C). CLP animals showed TNF and RNH1 concentrations of  215.4 
± 57.86 pg/mL and 4.68 ± 0.73 ng/mL, respectively (both n = 8; Figure 7, A and C). However, when com-
pared with vehicle-treated animals, the treatment with RNase 1 resulted in a decrease in the concentrations of  
Figure 3. RNase 1 treatment of cardiomyocytes exposed to 
necrotic cardiomyocytes results in decreased apoptosis. Car-
diomyocytes exposed to 105 necrotic cardiomyocytes in presence 
(RNase + NC) or absence (NC) of 2.8 U/mL RNase 1 for 16 hours 
compared with unstimulated cells (control) were analyzed (all n 
= 3). (A) Apoptotic cells were labeled with TUNEL (red) and the 
nuclei of cardiomyocytes stained with DAPI (blue). Scale bars: 100 
μm. (B) Quantification of TUNEL fluorescence. A 1-way ANOVA 
followed by Bonferroni test was used for multiple comparisons. 
Data are presented as dot plot with the mean ± SEM. (C) Treated 
HL-1 cells were stained with annexin V and 7-AAD and analyzed 
by flow cytometry. Gate I (bottom left) displays the living cells. 
The annexin V+ cells are shown in Gate II (top left) and represent 
the apoptotic cardiomyocytes. The double-positive cells are 
demonstrated in gate III (top right) and in gate IV (bottom right), 
where the 7-AAD+ or necrotic cells are located. (D) The percent-
age of annexin V+ (apoptotic) cells is displayed. A 1-way ANOVA 
followed by Bonferroni test was used for multiple comparisons. 
Data are presented as dot plot with the mean ± SEM. §P < 0.05 
versus control; #P < 0.05 versus NC. NC, necrotic cardiomyocytes; 
RNase, ribonuclease 1.
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TNF (41.1 ± 17.90 pg/mL; P < 0.05; Figure 7A) and RNH1 (3.83 ± 1.15 ng/mL; Figure 7C). In addition, we 
found a significant correlation between TNF and RNase 1 concentration in CLP mice treated with vehicle or 
RNase 1 (both P < 0.05; Figure 7, F and G). Figure 7D shows the corresponding eRNA levels of  the individ-
ual groups (Figure 7D). To gain a better understanding of  the RNase 1 expression in sepsis, we performed a 
time course of  RNase 1 serum levels in CLP-sepsis (Figure 7E). We detected a significant decrease of  RNase 
1 serum levels in CLP-sepsis compared with sham-operated mice at all time points (all P < 0.05; Figure 7E). 
The highest RNase 1 serum levels in CLP-sepsis could be measured 1 hour after sepsis induction by CLP 
(177.21 ± 62.78). We detected the lowest RNase 1 serum levels at 3 hours after surgery (11.43 ± 1.20), with 
the levels increasing again (52.14 ± 18.59) at 24 hours after surgery.
Discussion
Septic cardiomyopathy is a life-threatening organ dysfunction associated with a complicated postopera-
tive course and increased mortality. Despite intense efforts in basic and clinical research, therapy for this 
condition is supportive in nature, as no specific therapy is available (5). This urgently necessitates a better 
understanding of  the underlying pathophysiology and most importantly, the identification of  new thera-
peutic targets and strategies. This study provides the first evidence to our knowledge that RNase 1 reduces 
cardiac apoptosis and attenuates septic cardiomyopathy by reducing the levels of  circulating eRNA in a 
murine model of  polymicrobial sepsis.
Specifically, we report for the first time to our knowledge that the levels of  RNH1, the endogenous 
inhibitor of  RNase 1, are significantly elevated on the day of  diagnosis and 3 days after diagnosis of  sepsis 
(Figure 1A). We have also recently reported an increased serum expression of  RNase 1 at the onset of  
sepsis (22). RNH1 specifically binds to RNase 1 and inhibits its activity (20). Based on these findings, we 
hypothesized that an increase in RNH1 expression results in an increase of  eRNA levels, owing to inhibi-
tion of  the enzymatic activity of  RNase 1 by RNH1 (Figure 8). Indeed, we found significantly elevated lev-
Figure 4. RNase 1 treatment or TLR3 inhibition 
results in decrease of caspase-3 activation and 
TNF expression in murine cardiomyocytes 
exposed to serum of septic patients or RNA. 
(A) Cardiomyocytes exposed to 5 % serum 
of patients with sepsis (SsP) for 16 hours in 
presence (RNase + SsP; n = 4) or absence of 2.8 
U/mL RNase 1 (n = 3) were stained with DAPI 
and anti-cleaved caspase-3 and compared with 
unstimulated cells (control; n = 3). DAPI stained 
the nuclei (blue) and the green immunofluo-
rescence represents the cleaved caspase-3 (cl. 
caspase 3) expression. Scale bars: 50 μm. (B) 
Quantification of cleaved caspase-3 immu-
nofluorescence. A 1-way ANOVA followed by 
Bonferroni test was used for multiple compar-
isons. Data are presented as dot plot with the 
mean ± SEM. (C) Relative TNF mRNA expression 
of cardiomyocytes exposed to SsP in presence 
of RNase 1 compared with cardiomyocytes 
stimulated in absence of RNase 1 (both n =3). An 
unpaired t test (2-tailed) was used for statistical 
analysis. Data are presented as dot plot with the 
mean ± SEM. (D) Relative caspase activity was 
analyzed in cardiomyocytes exposed to 100 ng/
mL eRNA and unstimulated cells for 16 hours in 
presence (both n = 3) or absence (both n = 5) of 
2 μM TLR3-Inhibitor using Caspase Glo assay. A 
1-way ANOVA followed by Bonferroni test was 
used for multiple comparisons. Data are present-
ed as dot plot with the mean ± SEM. §P < 0.05 
versus control; #P < 0.05 versus SsP. SsP, serum 
of septic patients; RNase, ribonuclease 1.
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els of  free circulating eRNA in serum of  septic patients (Figure 1B). The tissue injury and cell death in sep-
sis and septic shock leads to a loss of  tissue integrity and subsequently to the release of  both cell-free DNA 
and eRNA into the circulation (26). Although there is good evidence that cell-free DNA plays a crucial role 
in the crosstalk between tissue injury, inflammation, and coagulation, very little is known about the physio-
logical and pathophysiological roles of  eRNA in sepsis (27). It has been suggested that the negative charge 
of  eRNA builds the structural feature rendering eRNA capable of  activating factor XII and, hence, coagu-
lation (28, 29). Moreover, Chen and colleagues report that eRNA contributes to myocardial inflammation 
via TLR-3-Trif  signaling (23). Whether eRNA plays a role in cardiac apoptosis, which plays a pivotal role 
in the pathophysiology of  septic cardiomyopathy, however, was not known. To address this important 
question, we exposed cardiomyocytes to NC or serum of  septic shock patients (Figure 2, Figure 3, and 
Figure 5). In line with the work from Chen and colleagues, we used NC (as our source of  eRNA) to stim-
Figure 5. RNase 1 treatment of mice with polymicrobial sepsis resulted in an improved heart function. (A) Repre-
sentative echocardiography images of each group are shown. (B) The ejection fraction, (C) fractional shortening, (D) 
fraction area change, (E) left ventricular end-diastolic volume (LVEDV), (F) left ventricular end-systolic volume (LVESV), 
(G) stroke volume (SV), (H) cardiac output and (I) heart rate before echocardiography of sham-operated mice treated 
with vehicle (n = 12) or RNase 1 (n = 5) and mice with polymicrobial sepsis induced by CLP treated with vehicle or RNase 
1 were analyzed (both n = 12). Individual values are plotted as mean ± SEM. A 1-way ANOVA followed by Bonferroni 
test was used for multiple comparisons (graph B–I). §P < 0.05 versus sham; #P < 0.05 versus CLP + vehicle. CLP, cecal 
ligation and puncture; RNase, ribonuclease 1.
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ulate cardiomyocytes with eRNA (23). This approach enabled us to expose cardiomyocytes to the eRNA 
contained in cardiomyocytes, which contain several types of  RNA (e.g., miRNA, tRNA, and siRNA) (10). 
In addition to the free circulating, extracellular RNA, in both stimulants (NC and serum of  septic patients) 
a part of  the RNA may be encapsulated in extracellular vesicles such as exosomes or microvesicles and, 
thus, be protected from the digestion of  RNase 1 (30, 31). Nevertheless, we were able to show that RNase 
1 significantly reduces both apoptosis and inflammation in murine cardiomyocytes (Figure 2, Figure 3, and 
Figure 4). To standardize our model, we first measured the total amount of  eRNA in the cell supernatant 
of  cardiomyocytes exposed to NC (Figure 2D). In fact, we found an increased release of  eRNA into the 
cell supernatant of  cardiomyocytes exposed to NC compared with the cell supernatant of  untreated cardio-
myocytes (Figure 2D). Additionally, we found a significant activation (measured as cleavage) of  caspase-3 
Figure 6. RNase 1 treatment of mice with polymicrobial sepsis resulted in a decreased cardiac apoptosis. Heart tissue of sham-operated mice (n = 4) or mice 
with polymicrobial sepsis induced by CLP treated with vehicle or RNase 1 (both n = 5) were analyzed by Western blot. To analyze the intrinsic apoptosis signal-
ing pathway, (A) Bax and (B) Bcl-2 levels as well as (C) caspase-9 and (D) caspase-3 activation were investigated. A 1-way ANOVA followed by Bonferroni test 
was used for multiple comparisons. Data are presented as dot plot with the mean ± SEM. Representative immunoblots are presented above the bar charts. 
The quantified OD of bands was corrected for the corresponding tubulin bands and normalized using the related sham band. Heart tissue of sham-operated 
mice treated with vehicle or RNase or mice with polymicrobial sepsis induced by CLP also treated with vehicle or RNase 1 (all n = 5) were analyzed by TUNEL 
labeling. (E) Apoptotic cells were labeled with TUNEL (red) and the nuclei of cardiomyocytes stained with DAPI (blue). Scale bars: 100 μm. (F) Quantification of 
TUNEL fluorescence. A 1-way ANOVA followed by Bonferroni test was used for multiple comparisons. Data are presented as dot plot with the mean ± SEM. §P 
< 0.05 versus Sham; #P < 0.05 versus CLP + Vehicle. CLP, cecal ligation and puncture; RNase, ribonuclease 1; Bcl-2, B-cell lymphoma 2.
9insight.jci.org   https://doi.org/10.1172/jci.insight.131571
R E S E A R C H  A R T I C L E
and consecutive induction of  apoptosis by exposing murine cardiomyocytes to either NC or, notably, serum 
of  septic patients (Figure 2 and Figure 4). Furthermore, to address the question as to whether the observed 
increase in apoptosis is caused by eRNA, we exposed cardiomyocytes to eRNA isolated from cardiomy-
ocytes. Indeed, we found a significant increase in caspase-3 activation in cardiomyocytes challenged with 
eRNA compared with unstimulated cells (Figure 4D). In line with Chen and colleagues, we showed that 
eRNA contributes to induction of  apoptosis (caspase-3 activation) via TLR3 signaling (Figure 4D and ref. 
23). Having shown that sepsis is associated with elevated RNH1 levels, we next aimed to investigate the 
potential protective/therapeutic effects of  RNase 1.
Here, we report for the first time to our knowledge that RNase 1 attenuates caspase-3 activation and 
apoptosis in cardiomyocytes exposed to either NC or, as a reverse translational approach, to the serum of  
septic patients. Previous studies have investigated the therapeutic potential of  a reduction/inhibition of  
apoptosis by direct/specific caspase-inhibition in animal models of  cardiomyopathy induced by ischemia/
reperfusion and rapid ventricular pacing (32, 33). Cabrera-Fuentes et al. reported that RNase 1 treatment 
reduces the infarct size caused by myocardial ischemia/reperfusion (34). Furthermore, they measured a 
reduction in necrotic cell death in ischemic hearts treated with RNase 1 compared vehicle treatment (34). 
In addition, there is also good evidence that eRNA released from necrotic cells triggers the release of  proin-
flammatory cytokines, whereas RNase 1 reduces the formation of  cytokines (23, 24), which play a key 
role in septic cardiomyopathy and cardiac apoptosis (35, 36). We report here that RNase 1 attenuates TNF 
Figure 7. RNase 1 treatment of mice with polymicro-
bial sepsis resulted in a decreased TNF expression. 
(A) TNF, (B) RNase 1 and (C) RNH1 serum levels of 
sham-operated mice treated with vehicle (n = 11) 
or RNase 1 (n = 5) or mice with polymicrobial sepsis 
induced by CLP treated with vehicle (n = 8) or RNase 
1 (n = 9) were analyzed by ELISA. An unpaired t test 
(2-tailed) was used for statistical analysis (A and C). 
In B, a 1-way ANOVA followed by Bonferroni test was 
used for multiple comparisons. Data are presented 
as dot plot with the mean ± SEM. (D) Total extra-
cellular RNA in serum of mice are demonstrated. A 
1-way ANOVA followed by Bonferroni test was used 
for multiple comparisons. Data are presented as 
dot plot with the mean ± SEM. (E) RNase 1 serum 
levels over the time in sham-operated mice (n = 3) 
and mice with polymicrobial sepsis induced by CLP 
treated with vehicle (n = 4). Correlation of TNF and 
RNase 1 of mice with polymicrobial sepsis induced 
by CLP (F) treated with vehicle and (G) treated with 
RNase 1. §P < 0.05 versus sham; #P < 0.05 versus CLP 
+ vehicle. CLP, cecal ligation and puncture; RNase, 
ribonuclease 1; RNH1, ribonuclease-inhibitor 1.
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mRNA expression in cardiomyocytes exposed to either NC or serum of  septic patients. Thus, RNase 1 may 
attenuate septic cardiomyopathy by reducing both cardiac apoptosis and cytokine production.
To gain a better insight into the roles of  RNH1, RNase 1 and eRNA in septic cardiomyopathy in vivo, we 
used a murine model of  polymicrobial sepsis. Having shown increased serum levels of  RNase 1 in patients 
at the early phase (onset) of  sepsis (22), we detected significantly lower RNase 1 serum levels in CLP mice 
(at 24 hours after onset of  sepsis). Owing to the very short half-life of  RNase 1 as well as the inhibition 
of  RNase 1 by RNH1 may all be reasons, which either individually or in combination, contributing to the 
differences observed. In line with our findings in human sepsis, we found that the levels of  RNH1 are signifi-
cantly elevated in mice with polymicrobial sepsis (Figure 7C). Based on these findings, we propose that an 
increase in RNH1 expression results in a decreased RNase 1 expression/enzymatic activity, which results in 
an increase in circulating eRNA, leading to a release of  proinflammatory cytokines (Figure 8). To substantiate 
this hypothesis, we have investigated the effect of  RNase 1 as a therapeutic target on the cardiac dysfunction 
associated with sepsis. We confirm that the model of  polymicrobial sepsis used here, indeed, results in a sub-
stantial cardiac dysfunction defined by a significant decrease in EF, FS, and fraction area change (Figure 5). 
Stieger et al. reported an increase of  FS in mice treated with RNase 1 (50 μg/kg) compared with mice treated 
with saline 24 hours after myocardial infraction (37).We also detected a significant reduction in left ventric-
ular cardiac dysfunction in CLP mice treated with RNase 1, as determined by a substantial increase in EF, 
FS, fraction area change, and cardiac output (Figure 5). Moreover, we detected a significant reduction in the 
release of  TNF in CLP mice treated with RNase 1 when compared with CLP mice treated with vehicle (Fig-
ure 7A). Additionally, we found a negative correlation between the RNase 1 and TNF concentration; higher 
RNase 1 serum levels were associated with lower TNF levels (Figure 7, E and F). These findings support the 
hypothesis that eRNA released from necrotic cells triggers the release of  proinflammatory cytokines, whereas 
RNase 1 reduces the formation of  cytokines by cleaving eRNA (Figure 8). Notably, treatment of  CLP mice 
with RNase 1 reduced the cardiac dysfunction associated with sepsis.
Figure 8. Proposed pathway and pathophysiologic role of eRNA, RNase 1, and RNH1 in septic cardiomyopathy. eRNA belongs to the heterogeneous 
group of DAMPs and is released as a result of sepsis-associated tissue injury and necrotic cell death. eRNA binds to the pattern recognition receptors toll-
like receptor 3 located on the endosome, which results in the formation of TNF in cardiomyocytes. TNF binds to TNFR and induces pro-apoptotic as well as 
pro-inflammatory pathways. RNases belong to a group of host-defense peptides secreted from endothelial cells and thereby cleave eRNA. RNH1 binds to 
RNase 1 and inactivates the host-defense function of RNases, which allows eRNA to bind to TLR. eRNA, extracellular RNA; RNase 1, ribonuclease 1; RNH1, 
ribonuclease-inhibitor 1; TNFR, TNF receptor.
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We also investigated the sepsis-associated degree of  cardiac apoptosis in our murine model of  polymi-
crobial sepsis. The induction of  apoptosis can be triggered by either the intrinsic or the extrinsic pathway. 
Several studies have shown that cytochrome C and Apaf-1 form an apoptosome, which activates caspase-9 
(38), which, in turn, activates caspase-3. Activated caspase-3 then initiates and drives apoptosis. Indeed, 
we observed a relevant activation of  the intrinsic apoptosis signaling pathway in murine hearts from mice 
with polymicrobial sepsis, indicated by a significant increase in Bax levels, activation of  caspase-9 and 
caspase-3 and a decrease of  Bcl-2 (Figure 6). Furthermore, we measured increased apoptosis induction in 
heart tissue by TUNEL labeling (Figure 6). In line with our findings, Hotchkiss et al. reported as early as 
1999 that apoptosis in the spleen of  septic patients also occurs through the intrinsic apoptosis pathway (39). 
Treatment of  CLP mice with RNase 1 resulted in a reduction of  the activation of  apoptosis in the heart. 
Most notably, treatment of  septic mice with RNase 1 attenuated the rise in cardiac Bax levels, activation of  
caspase-9 and caspase-3, the decrease in Bcl-2 and TUNEL+ cells caused by sepsis in the heart (Figure 6). 
In line with our findings, Stieger et al. reported a reduction of  apoptosis 24 hours after ligation of  the left 
anterior descending artery (LAD) in mice treated with RNase 1 (37). Treatment with RNase 1 in sham-op-
erated mice did not show any apoptosis induction (Figure 6). These results indicate that excessive amounts 
of  eRNA drive apoptosis in the heart by activating the intrinsic apoptosis pathway. However, in contrast 
to the eRNA serum levels of  septic patients, we could not detect any difference in eRNA expression in 
CLP mice compared with sham-operated mice (Figure 7D). One possible reason for the different results 
may be the different time points of  the measurements. Whereas eRNA concentration was measured in 
patients with sepsis 3 days after diagnosis, the concentration of  eRNA in mice was measured 24 hours after 
CLP-sepsis induction. This hypothesis is also confirmed by Stieger and colleagues, who reported increased 
eRNA levels within 30 minutes and maximal eRNA levels at 2 hours after ligation of  the LAD. However, 4 
hours after ligation of  LAD, the eRNA levels had returned to baseline (37).
In conclusion, our data show for the first time to our knowledge that sepsis results in a significant 
increase in eRNA and RNH1, the endogenous inhibitor of  RNase 1. We found that RNase 1 reduces 
apoptosis as well as TNF expression in murine cardiomyocytes induced by NC or serum of  septic patients. 
In addition, treatment with RNase 1 reduces the degree of  (a) cardiac apoptosis induced by the intrinsic 
pathway, (b) TNF expression, and (c) cardiac dysfunction caused by polymicrobial sepsis in mice. Based on 
these findings, we propose that (a) eRNA plays a significant role in the pathophysiology of  the organ (car-
diac) dysfunction in sepsis and (b) RNase may be a new therapeutic strategy to reduce the cardiac injury 
and dysfunction caused by sepsis.
Methods
Study population. The blood samples of  septic ICU patients (n = 21) were collected during the first 18 hours 
and 3 days after diagnosis of  sepsis defined by the 2012 Surviving Sepsis Campaign Guidelines using an 
intravascular catheter (40). Age- and sex-matched healthy subjects were used as controls (n = 10).
Serum sampling. After 10 minutes of  coagulation at room temperature, the serum samples were centri-
fuged at 2000 g for 10 minutes and stored at –80°C (22). The characteristics of  the study population are 
shown in Supplemental Table 1 according to the groups: healthy subjects, patient with sepsis on the day of  
diagnosis (Sepsi DD), and patients with sepsis 3 days after diagnosis (Sepsis D3).
ELISAs. The levels of  the RNH1 and RNase 1 in human and mice serum were determined using a com-
mercial ELISA kit (LifeSpan BioSciences). According to the manufacturer, no significant cross-reactivity 
or interference between Ribonuclease A/RNASE1 and analogs is known. Furthermore, the ELISAs do not 
distinguish between bound RNase 1 and unbound RNase 1 with RNH1. Mouse TNF-α DuoSet ELISA kit 
(R&D Systems) was used to measure the TNF serum levels in mice. The optical density was measured at 
450 nm using a microplate reader (Tecan Group).
Total eRNA analyzation and screening. Total eRNA in serum of healthy subjects (n = 10) and septic patients 3 
days after diagnosis (n = 21) were analyzed using QuantiFlour RNA System and Quantus Fluorometer (Prome-
ga). For RNA size quantification cell-free RNA was isolated from serum of healthy subjects and patients with 
sepsis by the Quick-cfRNA Serum & Plasma Kit (Zymo Research). The 4200 TapStation system and the high 
sensitivity RNA ScreenTape Assay (Agilent) were used for analyzing the RNA molecules from 50 to 6000 nt.
Cell culture. HL-1 cells, a mouse atrial cell line, were provided by William C. Claycomb (Departments 
of  Biochemistry and Molecular Biology and Cell Biology and Anatomy, Louisiana State University Med-
ical Center, New Orleans, Louisiana, USA) (41). Briefly, HL-1 cells were cultured on gelatin/fibronec-
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tin-coated plates and maintained in Claycomb-Medium (Sigma-Aldrich) supplemented with 10% fetal calf  
serum (Biochrom), 0.1 mM norepinephrine (Sigma-Aldrich), 2 mM L-glutamine (Sigma-Aldrich), and 1% 
penicillin/streptomycin (Invitrogen) under an atmosphere of  5% CO2 at 37°C (42–45). Cardiomyocytes 
were exposed to 1 × 105 NC per milliliter of  medium or to 5% septic patient serum in the presence or 
absence of  2.8 U/mL RNase 1 (Invitrogen) for 16 hours. Unstimulated cells were used as negative control.
NC. NC were generated by 3 circles of  freezing at –80°C and thawing at 37°C (23). Necrosis was veri-
fied by trypan blue staining. Necrotic cells (1 × 106 cells/mL) were stored at –80°C.
RNA extraction of  cardiomyocytes. HL-1 cells were cultivated as described before and harvested by scraping 
(45). After 3 washing cycles with PBS the RNA was isolated using the NucleoSpin RNA Kit (Macherey-Nagel).
Cell stimulation. Cardiomyocytes were exposed to 1 × 105 necrotic cardiomyocytes per milliliter medi-
um or to 5% serum of  septic patients in the presence or absence of  2.8 U/mL RNase 1 (Invitrogen) for 16 
hours. Unstimulated cells were used as negative control. Furthermore, cardiomyocytes were exposed to 100 
ng/mL RNA in presence or absence of  2 μM CU CPT 4a (TLR3 inhibitor, Tocris Bioscience).
Immunofluorescence of  cleaved caspase-3. The amount of  cleaved caspase-3 was analyzed using immuno-
fluorescence. As described previously (45), HL-1 cells were grown on coverslips and exposed to necrotic 
cardiomyocytes or serum of  septic patients in presence or absence of  2.8 U/mL RNase 1 for 16 hours. 
Afterward, cells were fixed with 4% formaldehyde (Sigma-Aldrich) for 15 minutes at room temperature. 
After 3 washing cycles using PBS, cells were blocked with blocking buffer (5% BSA and 0.3% Triton X-100 
in PBS) for 1 hour. The cardiomyocytes were, then, incubated with a primary antibody directed against 
cleaved caspase-3 (Cell Signaling), diluted 1:200 in antibody dilution buffer (1% BSA and 0.3% Triton 
X-100 in PBS) over night at 4°C. After 3 washing cycles, the cardiomyocytes were incubated with a second-
ary antibody (Invitrogen) diluted 1:1000 in antibody dilution buffer for 2 hours at room temperature in the 
dark. Coverslips were washed as described before and covered with ProLong Gold (Invitrogen) containing 
DAPI for nuclei staining. Immunofluorescence was detected using LSM 710 confocal microscope (Zeiss) 
and quantified by ImageJ software (NIH).
TUNEL labeling. As described previously (45), HL-1 cells were grown in 12-well plates on coverslips 
coated with gelatin/fibronectin. HL-1 cells were fixed with 4% formaldehyde for 1 hour at room tempera-
ture after exposure with necrotic cells in the presence or absence of  RNase 1 for 16 hours. After washing, 
cells were permeabilized with 0.1% Triton X-100 for 2 minutes on ice. Next, cells were labeled using the In 
Situ Cell Death Detection Kit TMR red (Roche) as described (45). Coverslips were covered with 15 μL of  
ProLong Gold. Unstimulated cells were used as negative control. The paraffin-embedded heart tissues were 
dewaxed by a series of  alcohol and washed twice in PBS. The tissues were permeabilized in the microwave 
with 0.1 M citrate buffer (pH 6.0) for 5 minutes by 350 W. After cooling down the tissues were labeled also 
using the In Situ Cell Death Detection Kit TMR red (Roche) and covered with ProLong Gold. An LSM 
710 confocal microscope (Zeiss) and ImageJ software were used to detect and quantify apoptotic cells.
Relative TNF mRNA expression. RNA was isolated using Trizol reagent, as described previously (45). 
The following primers were used to analyze the relative mRNA expression of  TNF in the quantitative 
real-time PCR (StepOnePlus Real-Time PCR System; Thermo Fisher Scientific, MA, USA): TNF 5′ 
TCCCCAAAGGGATGAGAAG 3′ (for) and 5′ GCACCACTAGTTGGTTGTC 3′ (rev), S7 5′ GGTG-
GTCGGAAAGCTATCA 3′ (for) and 5′ AAGTCCTCAAGGATGGCGT 3′ (rev). Relative quantification 
was performed by using Microsoft Excel.
Flow cytometry. The amount of  cell death was analyzed as described previously by using flow cytometry 
(45). Stimulated cardiomyocytes were harvested by scraping. After 3 washing cycles with PBS, the super-
natant was discarded and cells were resuspended in binding buffer as described in the APC Annexin V 
Apoptosis Detection Kit (BD Pharmingen). Cells were stained with APC Annexin V Apoptosis Detection 
Kit and analyzed by FACSCanto-II (BD Biosciences). In addition, renal dysfunction and hepatocellular 
injury were analyzed in the serum of  all mice, as shown in the Supplemental Methods
Caspase-3 activity. To analyze caspase-3 activity 1.5 × 104 cardiomyocytes/well were seeded in a 96-well 
white plate. After 24 hours the cells were exposed with 100 μL of  medium containing RNA in presence 
and absence of  TLR3 inhibitor. Untreated cells were used as negative control. The caspase-3 activity was 
analyzed by adding 100 μL of  Caspase-Glo 3/7 Assay reagent (Promega Corporation). The luminescence 
was detected after 30 minutes of  incubation at room temperature using microplate reader (Tecan Group).
Murine polymicrobial sepsis model. For this study, 10-week-old, male C57BL/6 mice were used. CLP 
was performed to induce polymicrobial sepsis as previously described (46, 47). Surgery was performed 
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under anesthesia by isoflurane (3%) delivered in oxygen at a rate of  1 L/min in an anesthetic chamber and 
maintained with isoflurane (2%) and oxygen (1 L/min) via a face mask. Buprenorphine (0.05 mg/kg, i.p.) 
was administered just before starting the surgery to obtain adequate analgesia. Under anesthesia, the abdo-
men was opened, the cecum was totally ligated below the ileocecal valve and punctured at both opposite 
ends using an 18-G needle, where a small amount of  feces was squeezed out. As control, sham- operated 
mice (without CLP) were used. For fluid resuscitation, normal saline (0.9% NaCl) was administered into 
the mouse’s abdomen before closure (5 mL/kg) and administrated directly after surgery (10 mL/kg s.c.). 
Antibiotics (Imipenem/Cilastatin; 0.25 mg dissolved in fluid resuscitation 7.5 mL/kg 0.9% NaCl, s.c.) and 
analgesia (Buprenorphine; 0.05 mg/kg, i.p.) were injected 6 and 18 hours after surgery. RNase 1 or its vehi-
cle was administrated before sepsis induction (50 μg/kg RNase 1 or 0.9% NaCl, i.v.), directly after surgery 
(200 μg/100 μL RNase 1 or 100 μL 0.9% NaCl, s.c.), and 4 hours after surgery (500 μg/100 μL RNase 1 
or 100 μL 0.9% NaCl, s.c.). The surgeon was blinded to vehicle or treatment group. After 24 hours, cardiac 
function was assessed by echocardiography in vivo.
Echocardiography. Cardiac function was assessed 24 hours after CLP on the Vevo 3100 imaging sys-
tem (VisualSonics). Briefly, mice were sedated in an anesthetic chamber with isoflurane (3%) delivered in 
oxygen at a rate of  1 L/min and then transferred onto a thermoregulatory platform in the supine position, 
where anesthetic was maintained at: isoflurane (0.5%–2.0%) and oxygen (1 L/min). The fur was removed 
from the chest by Veet hair removal cream and prewarmed echo gel was then placed onto the shaven chest, 
where the following parameters of  cardiac function were measured via the MX550D imaging probe: per-
centage EF, percentage FS, and percentage FAC. After sacrifice of  the animals, the organs and blood were 
collected for further experiments. All analysis was conducted offline and blinded.
Protein isolation and Western blot analysis. Semiquantitative Western blot analysis of  caspase-3, caspase-9, 
Bax, and Bcl-2 was performed in murine heart tissue as previously before (48, 49). For protein isolation, 
the tissue was homogenized in homogenization buffer (20 mM HEPES, pH 7.9, 1 mM MgCl2, 0.5 mM 
EDTA, 1% Nonidet P-40, 1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 1 μL/mL PIC) and centrifuged by 
18,800 g for 40 minutes at 4°C. The protein concentration of  the supernatant was determined using the 
bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific). Proteins were separated by size using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride 
membrane. Unspecific bonds were blocked by incubating the membrane for 1 hour in blocking buffer (10% 
BSA in TBS containing 0.1% Tween). Following, the membrane was incubated with the primary antibody 
over night at 4°C diluted in 5% BSA in TBS containing 0.1% Tween. After 3 washing cycles, the membrane 
was incubated for 30 minutes with the HRP-conjugated secondary antibody. Protein bands were detected 
with enhanced chemiluminescent (ECL) detection system. The immunoreactive bands were visualized by 
autoradiography and the densitometric analysis was performed using Gel Pro Analyzer 4.5, 2000 software 
(Media Cybernetics). Results were normalized by using Tubulin as an endogenous control. The following 
primary antibodies from Cell Signaling were used: caspase-9 (C9) mouse (catalog 9508), Bcl-2 (D17C4) 
rabbit (catalog 3498), caspase-3 rabbit (catalog 9662), and Bax (D3R2M) rabbit (catalog 14796).
Statistics. The statistical analysis was performed with and the graphs were created with GraphPad Prism 
7. A 1-way ANOVA followed by Bonferroni test or unpaired 2-tailed t test was used for multiple comparisons 
with a significance level of  P < 0.05. The data represent the mean ± SEM of 3 independent experiments.
Study approval. All serum samples were collected in a study carried out by the Department of  Intensive 
Care and Intermediate Care at University Hospital RWTH Aachen and were stored in the centralized bio-
material bank (RWTH cBMB) after obtaining informed consent of  all study participants and approval by 
the local ethics committee (University Hospital RWTH Aachen; EK 206/09).
The Animal Welfare Ethics Review Board of  the Queen Mary University of  London approved the 
animal experimental protocols used in this study (Procedure Project License: PC5F29685). Animal care 
was in accordance with the guidelines of  the Home Office guidance on Operation of  Animals (Scientific 
Procedures Act 1986) published by Her Majesty’s Stationery Office and the Guide for the Care and Use of  
Laboratory Animals (National Academies Press, 2011).
Author contributions
EZ, LM, and CT conceived of  the manuscript and design. EZ, NW, LM, TS, SE, and GMN conducted 
all in vitro experiments and analyzed the data. CEO, EZ, LS, LM, CT, SMC, and BW conducted all in 
vivo experiments and data analyses. BD, TPS, CS, EZ, and LM performed all of  the eRNA measurements 
1 4insight.jci.org   https://doi.org/10.1172/jci.insight.131571
R E S E A R C H  A R T I C L E
and analyzed the data. FC, DC, MC, EZ, CT, and LM performed all Western blots and analyzed the data. 
EZ, GM, LM, and CT drafted and/or revised the manuscript for important intellectual content. All of  the 
authors reviewed and finally approved the manuscript.
Acknowledgments
This work was supported by an intramural grant to EZ (START 113/17), a grant from the German 
Research Foundation to LM (DFG, MA 7082/3-1), and a grant from the Federal Ministry of  Education 
and Research, Germany to SMC (BMBF 03Z22JN12, Research Group Translational Septomics, Centre 
for Innovation Competence Septomics). CT is funded by the Centre for Diabetic Kidney Disease, which 
is funded by the Barts and London Charity, and the William Harvey Research Foundation (WHRF). This 
work was supported by the RWTH centralized Biomaterial Database (RWTH cBMB) of  the University 
Hospital RWTH Aachen and by the Confocal Microscopy Unit, a core facility of  the Interdisciplinary 
Center for Clinical Research (IZKF) Aachen within the Faculty of  Medicine at RWTH Aachen University. 
The authors thank Nadine Frank, Daniel Hinkelmann, and Oliver Krenkel for excellent technical support.
Address correspondence to: Lukas Martin, Uniklinik RWTH Aachen, Intensive Care and Intermediate 
Care, Pauwelsstraße 30, 52074 Aachen, Germany. Phone: 49.0.241.8037606; Email: lmartin@ukaachen.
de. Or to: Chris Thiemermann, Queen Mary University London, The William Harvey Research Institute, 
Centre for Translational Medicine & Therapeutics, Charterhouse Square, London EC1M 6BQ, United 
Kingdom. Phone: 44.0.20.78822107; Email: c.thiemermann@qmul.ac.uk.
 1. Singer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810.
 2. SepNet Critical Care Trials Group. Incidence of  severe sepsis and septic shock in German intensive care units: the prospective, 
multicentre INSEP study. Intensive Care Med. 2016;42(12):1980–1989.
 3. Sato R, Kuriyama A, Takada T, Nasu M, Luthe SK. Prevalence and risk factors of  sepsis-induced cardiomyopathy: a retrospec-
tive cohort study. Medicine (Baltimore). 2016;95(39):e5031.
 4. Narváez I, et al. Incidence and evolution of  sepsis-induced cardiomyopathy in a cohort of  patients with sepsis and septic shock. 
Med Intensiva. 2018;42(5):283–291.
 5. Martin L, et al. The septic heart: current understanding of  molecular mechanisms and clinical implications. Chest. 
2019;155(2):427–437.
 6. Coldewey SM, et al. Elevation of  serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis. 
Sci Rep. 2016;6:27594.
 7. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1–5.
 8. Chan JK, et al. Alarmins: awaiting a clinical response. J Clin Invest. 2012;122(8):2711–2719.
 9. Zernecke A, Preissner KT. Extracellular Ribonucleic Acids (RNA) enter the stage in cardiovascular disease. Circ Res. 
2016;118(3):469–479.
 10. Dinger ME, Mercer TR, Mattick JS. RNAs as extracellular signaling molecules. J Mol Endocrinol. 2008;40(4):151–159.
 11. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovas-
cular disease? Circ Res. 2012;110(3):483–495.
 12. Tijsen AJ, Pinto YM, Creemers EE. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am J Physiol 
Heart Circ Physiol. 2012;303(9):H1085–H1095.
 13. Roy S, Sen CK. MiRNA in innate immune responses: novel players in wound inflammation. Physiol Genomics. 2011;43(10):557–565.
 14. Fabbri M, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 
2012;109(31):E2110–E2116.
 15. Kim NH, Kang PM. Apoptosis in cardiovascular diseases: mechanism and clinical implications. Korean Circ J. 2010;40(7):299–305.
 16. Benner SA. Extracellular ‘communicator RNA’. FEBS Lett. 1988;233(2):225–228.
 17. Koczera P, Martin L, Marx G, Schuerholz T. The Ribonuclease A superfamily in humans: canonical rnases as the buttress of  
innate immunity. Int J Mol Sci. 2016;17(8):E1278.
 18. Futami J, et al. Tissue-specific expression of  pancreatic-type RNases and RNase inhibitor in humans. DNA Cell Biol. 
1997;16(4):413–419.
 19. Dickson KA, Haigis MC, Raines RT. Ribonuclease inhibitor: structure and function. Prog Nucleic Acid Res Mol Biol. 2005;80:349–374.
 20. Lomax JE, Bianchetti CM, Chang A, Phillips GN, Fox BG, Raines RT. Functional evolution of  ribonuclease inhibitor: insights 
from birds and reptiles. J Mol Biol. 2014;426(17):3041–3056.
 21. Abtin A, et al. Degradation by stratum corneum proteases prevents endogenous RNase inhibitor from blocking antimicrobial 
activities of  RNase 5 and RNase 7. J Invest Dermatol. 2009;129(9):2193–2201.
 22. Martin L, et al. The Human Host Defense Ribonucleases 1, 3 and 7 are elevated in patients with sepsis after major surgery — A 
Pilot Study. Int J Mol Sci. 2016;17(3):294.
 23. Chen C, et al. Role of  extracellular RNA and TLR3-Trif  signaling in myocardial ischemia-reperfusion injury. J Am Heart Assoc. 
2014;3(1):e000683.
 24. Feng Y, et al. Cardiac RNA induces inflammatory responses in cardiomyocytes and immune cells via Toll-like receptor 7 signal-
ing. J Biol Chem. 2015;290(44):26688–26698.
1 5insight.jci.org   https://doi.org/10.1172/jci.insight.131571
R E S E A R C H  A R T I C L E
 25. Fischer S, Cabrera-Fuentes HA, Noll T, Preissner KT. Impact of  extracellular RNA on endothelial barrier function. Cell Tissue 
Res. 2014;355(3):635–645.
 26. Schneck E, et al. Plasma DNA and RNA differentially impact coagulation during abdominal sepsis-an explorative study. J Surg 
Res. 2017;210:231–243.
 27. Gould TJ, et al. Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis. Arterioscler Thromb Vasc Biol. 
2015;35(12):2544–2553.
 28. Kannemeier C, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S 
A. 2007;104(15):6388–6393.
 29. Garnett ER, et al. Phenotype of  ribonuclease 1 deficiency in mice. Rna. 2019;25(8):921–934.
 30. Waldenström A, Gennebäck N, Hellman U, Ronquist G. Cardiomyocyte microvesicles contain DNA/RNA and convey biologi-
cal messages to target cells. PLoS One. 2012;7(4):e34653.
 31. Chistiakov DA, Orekhov AN, Bobryshev YV. Cardiac extracellular vesicles in normal and infarcted heart. Int J Mol Sci. 
2016;17(1):E63.
 32. Laugwitz KL, et al. Blocking caspase-activated apoptosis improves contractility in failing myocardium. Hum Gene Ther. 
2001;12(17):2051–2063.
 33. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of  ischemia/reperfusion injury in rats by a caspase inhibitor. Circu-
lation. 1998;97(3):276–281.
 34. Cabrera-Fuentes HA, et al. RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-α in 
cardiac ischaemia/reperfusion injury. Thromb Haemost. 2014;112(6):1110–1119.
 35. Müller-Werdan U, Engelmann H, Werdan K. Cardiodepression by tumor necrosis factor-α. Eur Cytokine Netw. 1998;9(4):689–691.
 36. Krown KA, et al. Tumor necrosis factor α-induced apoptosis in cardiac myocytes. Involvement of  the sphingolipid signaling 
cascade in cardiac cell death. J Clin Invest. 1996;98(12):2854–2865.
 37. Stieger P, et al. Targeting of  extracellular RNA reduces edema formation and infarct size and improves survival after myocardial 
infarction in mice. J Am Heart Assoc. 2017;6(6):e004541.
 38. Li P, et al. Cytochrome c and dATP-dependent formation of  Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. 
Cell. 1997;91(4):479–489.
 39. Hotchkiss RS, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 
1999;27(7):1230–1251.
 40. Dellinger RP, et al. Surviving Sepsis Campaign: international guidelines for management of  severe sepsis and septic shock, 
2012. Intensive Care Med. 2013;39(2):165–228.
 41. Claycomb WC, et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of  the adult car-
diomyocyte. Proc Natl Acad Sci U S A. 1998;95(6):2979–2984.
 42. Martin L, et al. Peptide 19-2.5 inhibits heparan sulfate-triggered inflammation in murine cardiomyocytes stimulated with 
human sepsis serum. PLoS One. 2015;10(5):e0127584.
 43. Martin L, Koczera P, Zechendorf  E, Schuerholz T. The endothelial glycocalyx: new diagnostic and therapeutic approaches in 
sepsis. Biomed Res Int. 2016;2016:3758278.
 44. Martin L, et al. Soluble heparan sulfate in serum of  septic shock patients induces mitochondrial dysfunction in murine cardio-
myocytes. Shock. 2015;44(6):569–577.
 45. Zechendorf  E, et al. Heparan sulfate induces necroptosis in murine cardiomyocytes: a medical-in silico approach combining in 
vitro experiments and machine learning. Front Immunol. 2018;9:393.
 46. Al Zoubi S, et al. Linagliptin attenuates the cardiac dysfunction associated with experimental sepsis in mice with pre-existing 
type 2 diabetes by inhibiting NF-κB. Front Immunol. 2018;9:2996.
 47. Martin L, et al. The synthetic antimicrobial peptide 19-2.5 attenuates septic cardiomyopathy and prevents down-regulation of  
SERCA2 in polymicrobial sepsis. Sci Rep. 2016;6:37277.
 48. Yamada N, et al. Novel synthetic, host-defense peptide protects against organ injury/dysfunction in a rat model of  severe hem-
orrhagic shock. Ann Surg. 2018;268(2):348–356.
 49. Sordi R, et al. Inhibition of  IκB kinase attenuates the organ injury and dysfunction associated with hemorrhagic shock. Mol 
Med. 2015;21:563–575.
